Wipro adds Rapid Trials for cost-effective data collection

10-Oct-2010 - Last updated on 11-Oct-2010 at 12:43 GMT

Wipro Technologies has introduced Rapid Trials to provide clients with a data collection platform that can be deployed quickly and with minimal infrastructure investment.

Rapid Trials is being offered on trial-by-trial or specific time-based pricing models designed to suit the needs of small- to mid-sized clients. Adopting these models allows India-based Wipro to on-board some clients in 10 weeks, compared to eight to 12 months using earlier processes.

Speed and flexibility are improved by eliminating the need for clients to make in-house infrastructure investments. Wipro hosts the platform on its IT infrastructure and this, coupled to the pricing models, is designed to help to small- to mid-sized firms standardise data collection.

NS Bala, senior vice president, manufacturing and life sciences business unit at Wipro, said: “The Wipro Rapid Trials solution is developed and designed to maximise the return on investment to the sponsors and provide faster time to market to help them develop drugs faster and safer.”

Also, Wipro says the platform shares resources across clinical trials, leading to total cost of ownership being 30 to 40 per cent lower. This is achieved without having to install and maintain in-house infrastructure.

Wipro has based the Rapid Trials platform on Oracle Life Sciences’ software suite. Using Oracle drug development software companies can standardise data collection processes and parameters across trials and geographies.

Neil de Crescenzo, senior vice president and general manager of Oracle's health sciences global business unit, said using its suite of software, such as Oracle Clinical and Oracle Remote Data Capture, helps standardise processes across partner channels and geographies.